|Inclusion Criteria:||1) Patients must have biopsy proven unresectable or locally recurrent hepatocellular cancer or intrahepatic cholangiocarcinoma. Patients with a single lesion must be 12 cm or less in greatest dimension. For patients with two lesions, no lesion may be greater than 10 cm in greatest dimension. For patients with three lesions, no lesion may be greater than 6cm in greatest dimension. Patients may have single or multinodular tumors (up to 3). There must be no evidence of extrahepatic tumor. Portal vein involvement or thrombosis is allowed.|
2) Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >/=20 mm with conventional techniques or as >/=10 mm with spiral CAT scan (CT).
3) Patients may have had prior chemotherapy, targeted biological therapy (ie sorafenib, etc...), surgery, transarterial chemoembolization (TACE), radiofrequency ablation, or cryosurgery for their disease as long as >/= 4 weeks from first protocol radiation treatment , (6 weeks for nitrosoureas or mitomycin C) . Patients may not have had prior radiation to the affected area.
4) Patients must be 18 years of age or older.
5) Expected survival must be greater than three months.
6) ECOG performance status </=2.
7) Participants must have normal organ and marrow function as defined below: Absolute neutrophil count (ANC) >/= 1,500/mcL, Platelets >/= 50,000/mcL, total bilirubin </= 4.0 X institutional upper limit of normal, AST (SGOT)/ALT (SGPT) </= 5.0 X institutional upper limit of normal, Creatinine </= 2mg/dl or creatinine clearance >/= 60 mL/min/1.73 m^2 (Calculated per Cockroft & Gault formula) for subjects with creatinine levels above institutional normal.
8) If patient has underlying cirrhosis, only Child-Pugh classification Group A or Group B patients should be included in this study. Clinical assessment of ascites and encephalopathy is required. Child-Pugh classification must be determined for all study participants at the time of eligibility analysis. Note albumin and PT/INR are required for Child-Pugh classification; these labs should be drawn with other labs required for eligibility analysis.
9) The effects of radiation on the developing human fetus are known to be teratogenic. Therefore, male and female patients of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Female patients of child bearing potential must also have a negative serum pregnancy test. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
10) Individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.
11) Ability to understand and the willingness to sign a written informed consent document.